106 related articles for article (PubMed ID: 11890331)
1. Monitoring the rates of composite events with censored data in phase II clinical trials.
Cheung YK; Thall PF
Biometrics; 2002 Mar; 58(1):89-97. PubMed ID: 11890331
[TBL] [Abstract][Full Text] [Related]
2. Continuous Bayesian adaptive randomization based on event times with covariates.
Cheung YK; Inoue LY; Wathen JK; Thall PF
Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549
[TBL] [Abstract][Full Text] [Related]
3. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
4. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Thall PF; Wathen JK; Bekele BN; Champlin RE; Baker LH; Benjamin RS
Stat Med; 2003 Mar; 22(5):763-80. PubMed ID: 12587104
[TBL] [Abstract][Full Text] [Related]
5. Design of Phase II cancer trials evaluating survival probabilities.
Case LD; Morgan TM
BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
[TBL] [Abstract][Full Text] [Related]
6. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.
Cai C; Liu S; Yuan Y
Stat Med; 2014 Oct; 33(23):4017-28. PubMed ID: 24817556
[TBL] [Abstract][Full Text] [Related]
8. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall PF; Simon RM; Estey EH
J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
10. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
11. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.
Wang J; Ma J; Cai C; Daver N; Ning J
Stat Med; 2021 Sep; 40(21):4629-4639. PubMed ID: 34101217
[TBL] [Abstract][Full Text] [Related]
13. Bayesian interim analysis of phase II cancer clinical trials.
Heitjan DF
Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
[TBL] [Abstract][Full Text] [Related]
14. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
Zohar S; Chevret S
Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
[TBL] [Abstract][Full Text] [Related]
15. Suspension of accrual in phase II cancer clinical trials.
Li Y; Mick R; Heitjan DF
Clin Trials; 2015 Apr; 12(2):128-38. PubMed ID: 25568092
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial.
Yuan Y; Huang X; Liu S
Stat Med; 2011 May; 30(11):1218-29. PubMed ID: 21432894
[TBL] [Abstract][Full Text] [Related]
17. Continuous event monitoring via a Bayesian predictive approach.
Di J; Wang D; Brashear HR; Dragalin V; Krams M
Pharm Stat; 2016; 15(2):109-22. PubMed ID: 26643012
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
19. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
Thall PF; Simon RM; Estey EH
Stat Med; 1995 Feb; 14(4):357-79. PubMed ID: 7746977
[TBL] [Abstract][Full Text] [Related]
20. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
